ABSTRACr The protective effect was examined of three doses (2, 10, and 20 mg) of sodium cromoglycate inhaled from a pressurised metered dose inhaler on the response to isocapnic hyperventilation of cold dry air in 10 asthmatic subjects. This was compared with the effect of cromoglycate powder (20 mg) inhaled from a Spincap and with placebo given on two occasions. The medications were inhaled on separate days, in random order and with the use of a double blind double dummy technique, 20 minutes before isocapnic hyperventilation of two fold increasing volumes of air (-15°C, 0% humidity) to produce a 20% fall in the post-treatment FEV1. Pretreatment of the asthmatic airway with inhaled sodium cromoglycate as dry powder, a nebulised solution, and pressurised aerosol can reduce the bronchoconstrictor response to exercise.' 5 Similar inhibition has been demonstrated after inhalation of cromoglycate solution (20 mg) and powder (20 mg),3 and after powder (20 mg) and pressurised aerosol (2 mg).5 The most effective dose of pressurised aerosol has not been established.
Pretreatment of the asthmatic airway with inhaled sodium cromoglycate as dry powder, a nebulised solution, and pressurised aerosol can reduce the bronchoconstrictor response to exercise.' 5 Similar inhibition has been demonstrated after inhalation of cromoglycate solution (20 mg) and powder (20 mg),3 and after powder (20 mg) and pressurised aerosol (2 mg).5 The most effective dose of pressurised aerosol has not been established.
Recent work by McFadden and coworkers has identified the importance of airway cooling in the development of exercise stimulated bronchoconstriction and has introduced a thermal challenge using maximal ventilation of cold dry air. 69 We have modified their method to allow the construc-tion of respiratory heat loss dose-response curves and have used it to examine the effect of drugs on bronchoconstriction stimulated by respiratory heat loss.10 13
In this study we compared the protective effect of three doses of cromoglycate aerosol (2, 10, and 20 mg) with powder (20 mg) and placebo on the response to respiratory heat loss in 10 adults with asthma, to identify the most effective dose of aerosol.
Methods
Ten adult asthmatics attending the Firestone regional chest and allergy unit participated in this study (table 1). All had a history of episodic wheeze and dyspnoea and described symptoms of exercise stimulated bronchoconstriction. All were atopic as shown by weal and flare responses to skin prick tests with 16 common allergen extracts. Over the period of the study, symptoms of asthma did not disturb sleep and the baseline FEV, before delivery of any test medication exceeded 70% of predicted normal. No subject had experienced symptoms of respiratory infection or been exposed to a sensitising allergen (with the exception of regular exposure to house dust in subjects 3 and 5-10) in the month preceding the study. The study was approved by the hospital research committee and each subject gave written informed consent. Each subject attended the laboratory at the same time of day on six test days within three weeks. Aerosol bronchodilator treatment was withheld for six hours and theophylline for 36 hours, but the use of beclomethasone was not interrupted; no subject used cromoglycate for control of asthma. After a 15 minute rest three measurements of FEV, spaced one minute apart were made with a 9 litre Collins water spirometer. The test medications were then given double blind in random order. They were: 1-placebo aerosol (four puffs), placebo powder; 2-placebo aerosol (four puffs), placebo powder; 3-cromoglycate aerosol (two puffs, 1 mg/puff), placebo aerosol (2 puffs), placebo powder; 4- cromoglycate aerosol (two puffs, 5 mg/puff), placebo aerosol (two puffs), placebo powder; 5-cromoglycate aerosol (4 puffs, 5 mg/puff), placebo powder; 6-placebo aerosol (four puffs), cromoglycate powder (20 mg The reliability of PD15 was examined by estimation of the within subject and between subject components of variance from a one way analysis of variance of the results from the two tests after placebo.
Reproducibility was quantified by the within subject standard deviation of PD15. The intraclass correlation, the ratio of between subject variance to the sum of between subject plus within subject variance, was used as a reliability coefficient. The intraclass correlation is the proportion of total variance due to real differences between subjects and can be thought of as a signal to noise ratio-or, more exactly, a signal to signal plus noise ratio. ' by analysis of covariance, the FEV1 being used as a covariate. This left the mean PD15 almost unchanged, so the differences in PD,5 after placebo and after cromoglycate treatments could not be explained as due to the difference in FEV,.
The within subject standard deviation of PD15 was 0-12 kcal (0.50 kJ)/min, which indicates that a within subject change of 0 35 kcal (1-46 kJ)/min or more would be unlikely to be due to measurement variability. Furthermore, the intraclass correlation for PDM5 was 0-91 (p < 0.0001), indicating good reliability when measurement variation is compared with true between subject differences.
Discussion
This study is the first to examine the protective effect of sodium cromoglycate aerosol inhaled from a pressurised inhaler on the response to hyperventilation of cold air. The results show that the lower dose of 2 mg is more effective than placebo and is as effective as the higher doses of 10 and 20 mg.
The effectiveness of cromoglycate powder in a 24 Patel observed increasing protection when estimated doses of 2-4, 12, and 24 mg were generated continuously by a Wright nebuliser and inhaled by tidal breathing over 5 minutes, and no greater protection after inhalation of 48 mg. Presumably the differences between the two studies are due to differences in the doses or distribution (or both) of cromoglycate deposited in the lung by the different methods of aerosol generation and inhalation. In our study the 2 mg dose of pressurised aerosol might have deposited an effective dose in the lung which was equal to or greater than the third dose of Patel et al,24 and therefore a higher dose would not have a greater effect. Alternatively, the different results between the two studies may be due to the different methods used to stimulate bronchoconstriction.
Two conflicting theories are currently held about the pathogenesis of exercise stimulated bronchoconstriction. Deal and coworkers25 concluded from a series of experiments using isocapnic hyperventilation of cold air that the major stimulus for exercise triggered bronchoconstriction was airway cooling without the release of chemical mediators. The alternative theory, proposed by Ben-Dov and his colleagues,26 suggests that exercise stimulated bronchoconstriction is primarily temperature independent and caused by mediator release. Recent findings by Lee and colleagues27 that mediator release does occur with respiratory heat loss, regardless of whether the cooling is achieved by exercise or by hyperventilation, incorporates aspects of both theories and is in keeping with the idea the cromoglycate attenuates bronchoconstriction provoked by both exercise and respiratory heat loss through its mast cell stabilising properties.
In practical terms, the results of this study and that of Bundgaard et al5 suggest that bronchoconstriction stimulated by cold air or by exercise will be equally inhibited by 2 mg of cromoglycate aerosol inhaled from a pressurised inhaler and by 20 mg of powder from a Spincap.
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